Placebo to ARGX-119 concentrate for solution for infusion clinical trials

A Phase 2a, Double-Blinded, Randomized, Placebo-Controlled, and Active-Treatment Extension Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of ARGX-119 in Participants With Amyotrophic Lateral Sclerosis

This study is looking at a new medicine called ARGX-119 for people with Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neurone Disease. It's an early-stage trial trying to find out if the medicine is safe, how well people tolerate it, and if it could help. Some people will get the active medicine, and others will get a dummy medicine.